A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy of Node Positive HER2 Negative Breast Cancer: The ABC Trial

Brief description of study

If you have been diagnosed with breast cancer and have completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer, you may qualify for this study. The main goal of this study will evaluate whether patients taking aspirin once per day will have a lower rate of cancer recurrence.


Clinical Study Identifier: s17-00022
ClinicalTrials.gov Identifier: NCT02927249
Principal Investigator: Francisco J Esteva
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.